Cybin Inc(CYBN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CYBN Cybin Inc

Market Closed 10-04 16:00:00 EDT

9.25

+0.41

+4.64%

盘后9.16

-0.09-0.97%

19:56 EDT

High9.50	Low8.75	Vol92.27K
Open8.96	D1 Closing8.84	Amplitude8.48%
Mkt Cap188.26M	Tradable Cap139.73M	Total Shares20.35M
T/O844.75K	T/O Rate0.61%	Tradable Shares15.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CYBN","market":"US","secType":"STK","nameCN":"Cybin Inc","latestPrice":9.25,"timestamp":1728072000000,"preClose":8.84,"halted":0,"volume":92270,"hourTrading":{"tag":"盘后","latestPrice":9.16,"preClose":9.25,"latestTime":"19:56 EDT","volume":1716,"amount":15796.51,"timestamp":1728086163517},"delay":0,"floatShares":15105500,"shares":20352747,"eps":-4.869346,"marketStatus":"Market Closed","change":0.41,"latestTime":"10-04 16:00:00 EDT","open":8.96,"high":9.5,"low":8.75,"amount":844750.4885399999,"amplitude":0.084842,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.869346,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1728288000000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":8.84,"preHourTrading":{"tag":"盘前","latestPrice":8.96,"preClose":8.84,"latestTime":"09:28 EDT","volume":740,"amount":6561.5504,"timestamp":1728048502678},"postHourTrading":{"tag":"盘后","latestPrice":9.16,"preClose":9.25,"latestTime":"19:56 EDT","volume":1716,"amount":15796.51,"timestamp":1728086163517},"volumeRatio":0.3791299776445493},"requestUrl":"/m/hq/s/CYBN","defaultTab":"news","newsList":[{"id":"2472691372","title":"Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2472691372","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472691372?lang=en_us&edition=fundamental","pubTime":"2024-10-03 19:30","pubTimestamp":1727955000,"startTime":"0","endTime":"0","summary":"TORONTO, October 03, 2024----Cybin Inc.   , a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET.The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include:. Cybin’s lead development programs CYB003 and CYB004 and upcoming clinical milestones.What differentiates Cybin’s development approach from other neuropsychiatric developments.Lessons learned and applied from the FDA’s Lykos NDA rejection.To listen to the event, please click here to register for the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.Cybin is a late-stage br","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/n4iuQxz6qRYDWrTz8XqXCA--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c08d1d68b8add4808ccbdab406adcf1e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/n4iuQxz6qRYDWrTz8XqXCA--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c08d1d68b8add4808ccbdab406adcf1e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-participate-water-tower-research-113000219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CYBN","BK4168"],"gpt_icon":0},{"id":"2472132132","title":"Cybin Expands Clinical Team to Support CYB003 Phase 3 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2472132132","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472132132?lang=en_us&edition=fundamental","pubTime":"2024-10-01 19:30","pubTimestamp":1727782200,"startTime":"0","endTime":"0","summary":"- Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder  imminently -. - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology -. - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 -. - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries -. TORONTO, October 01, 2024----Cybin Inc.   , a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QxVxOR9agD8UyrvnEtTJUQ--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a958e1c99740412ffa6ca5cf65b2a762","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QxVxOR9agD8UyrvnEtTJUQ--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a958e1c99740412ffa6ca5cf65b2a762"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-expands-clinical-team-support-113000596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CYBN","BK4007","BK4168","TISI","BK4120"],"gpt_icon":0},{"id":"2469082464","title":"Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2469082464","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469082464?lang=en_us&edition=fundamental","pubTime":"2024-09-24 19:30","pubTimestamp":1727177400,"startTime":"0","endTime":"0","summary":"TORONTO, September 24, 2024----Cybin Inc.   , a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin’s Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024.The panel discussion, titled \"Advancement in Psychedelic Therapies for Neuropsychiatry,\" will be webcast live on Thursday, September 26, 2024, at 10:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6UDGaVn64BSZBVePjMfx2w--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ba00ce5bc8f716079e28f0a8d7a12fba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6UDGaVn64BSZBVePjMfx2w--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ba00ce5bc8f716079e28f0a8d7a12fba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-participate-td-cowen-4th-113000848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4168","BK4127","BK4566","BK4211","SMMF","BK4207","COWN","TD","BK4007","CYBN"],"gpt_icon":0},{"id":"2469445117","title":"Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2469445117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469445117?lang=en_us&edition=fundamental","pubTime":"2024-09-24 16:15","pubTimestamp":1727165722,"startTime":"0","endTime":"0","summary":"Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Cybin (CYBN – Research Report) and increased the price target to $96.00 f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strong-buy-rating-for-cybin-inc-on-promising-clinical-advances-and-strategic-management-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strong-buy-rating-for-cybin-inc-on-promising-clinical-advances-and-strategic-management-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CYBN"],"gpt_icon":0},{"id":"2469152500","title":"Cybin Inc : Canaccord Genuity Cuts Target Price to $96 From $114","url":"https://stock-news.laohu8.com/highlight/detail?id=2469152500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469152500?lang=en_us&edition=fundamental","pubTime":"2024-09-23 14:11","pubTimestamp":1727071874,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240923:nFWN3L5031:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4168","CYBN","BK4007"],"gpt_icon":0},{"id":"2468479636","title":"Cybin Provides Corporate Update on Upcoming Clinical Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2468479636","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468479636?lang=en_us&edition=fundamental","pubTime":"2024-09-20 05:38","pubTimestamp":1726781880,"startTime":"0","endTime":"0","summary":"- Initiation of pivotal CYB003 Phase 3 study in Major Depressive Disorder  expected imminently -. - 12-month efficacy data from Phase 2 study of CYB003 in MDD expected in early Q4 2024 -. - Strengthened R&D team with addition of experienced drug development leaders Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek, as program leads for CYB003 and CYB004, respectively -. In August 2024, the Company held a productive Type B Initial Breakthrough Therapy Meeting with the U.S. Food and Drug Administration  in preparation for the imminent commencement of its CYB003 pivotal program in MDD. For the upcoming Phase 3 study, Cybin has selected 30 high quality clinical sites across the United States and Europe. The Phase 3 pivotal trial design incorporates several elements to address critical methodological issues such as functional unblinding that are considered important for drugs in this class.To date, results from a completed Phase 2 MDD study of CYB003 have shown rapid, robust improvements in sy","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WP6WIm2l88lxrq28qNugBg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1d47be36cb64bfe93c903006696658a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WP6WIm2l88lxrq28qNugBg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/1d47be36cb64bfe93c903006696658a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-provides-corporate-upcoming-clinical-213800419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CYBN","BK4007","ABVC","BK4139","BK4168"],"gpt_icon":0},{"id":"2468857820","title":"Cybin Announces Completion of Previously Announced Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2468857820","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468857820?lang=en_us&edition=fundamental","pubTime":"2024-09-19 19:26","pubTimestamp":1726745160,"startTime":"0","endTime":"0","summary":"TORONTO, September 19, 2024----Cybin Inc.   , a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company’s issued and outstanding common shares  on the basis of one new Common Share for every 38 existing Common Shares . The Consolidation is effective immediately and trading of the Common Shares reflecting the Consolidation will commence at the opening of trading today.As a result of the Consolidation, the 759,692,495 Common Shares issued and outstanding prior to the Consolidation have been reduced to approximately 19,991,907 Common Shares, subject to adjustment for treatment of fractional Common Shares. Each shareholder’s percentage ownership in the Company and proportional voting power remains unchanged after the Consolidation, except for minor changes and adjustments resulting from the t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gWFF8r2xnU4ecVP0vv20jw--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e28bf65cc8ad689db7ab463690c266a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gWFF8r2xnU4ecVP0vv20jw--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e28bf65cc8ad689db7ab463690c266a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-announces-completion-previously-announced-112600417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4168","BK4007","CYBN"],"gpt_icon":0},{"id":"2467672843","title":"Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested","url":"https://stock-news.laohu8.com/highlight/detail?id=2467672843","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467672843?lang=en_us&edition=fundamental","pubTime":"2024-09-16 21:38","pubTimestamp":1726493917,"startTime":"0","endTime":"0","summary":"These are the upcoming stock splits for the week of September 16 to September 20, based onTipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares . In this case, too, the market cap is maintained as the share price increases following the reverse stock split.Companies often undertake stock splits to improve the liquidity of the common shares and make them more affordable for retail investors. Let’s look quickly at the upcoming stock splits for the week.Purple Biotech  – Purple Biotech is a clinical-stage biotechnology company. Its technology harnesses the power of the tumor microenvironment  to overcome drug resistance and improve treatment outcomes fo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2dFDearZtv_6NXF8VWoUIA--~B/aD0zNTI7dz05NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/9db6a9c50891b3ede0498893757a20d2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2dFDearZtv_6NXF8VWoUIA--~B/aD0zNTI7dz05NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/9db6a9c50891b3ede0498893757a20d2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-september-133837938.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/upcoming-stock-splits-week-september-133837938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1023057109.AUD","BK4161","LU0359201612.USD","MKFG","IE00B12V2V27.USD","PPBT","BK4567","LU0266013472.USD","LU0359202008.SGD","BK4167","BK4007","AASZF","BK4531","IE00BYTNYN87.SGD","SG9999011746.SGD","BK4563","BK4108","BK4535","IE00BYQNZ168.SGD","BK4212","BK4539","KSCP","BK4548","BK4565","BK4157","LU2039709279.SGD","BK4552","CYBN","TME","ISPC","01698","BK4509","ZEPP","BK4526","BK4588","DECK","BK4168","BK4571","BK4146","BK4165"],"gpt_icon":0},{"id":"2467002333","title":"Wall Street Breakfast: The Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2467002333","media":"seekingalpha","labels":["Economic Data","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467002333?lang=en_us&edition=fundamental","pubTime":"2024-09-15 18:19","pubTimestamp":1726395564,"startTime":"0","endTime":"0","summary":"Legacy automakers scramble to counter 'existential threat' from nimble Chinese EV makersBest stock ideas going into the elections15 ‘Vintage Values’ names for 2025Try a barbell of Magnificent 7 and midcap techPalantir Chairman Thiel has filed to sell up to $1B in stock16 new GLP-1 weight-loss drugs could be launched by 202950 stocks that face tax-loss selling pressureLithium shares surge as world's biggest EV battery maker cuts output at major mine","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212395636/image_1212395636.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212395636/image_1212395636.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4721183-wall-street-breakfast-week-ahead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Economic Data,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BCDA","DJT","IE00BJTD4V19.USD","MSFT","IE00BJTD4N35.SGD","GIS","DRI","IRM","IE00BDRTCR15.USD","SCS","LU0477156953.USD","IE00BHPRN162.USD","US10Y.BOND","BK4590","US30Y.BOND","AIG","US12M.BOND","LU0072461881.USD","FERG","IE00B5949003.HKD","LU1721427968.SGD","FDS","FDX","ASTS","LU0097036916.USD","LEN","VTLE","US912797HE00.BOND","US7Y.BOND","ELTP","AVGO","IE00BFSS8Q28.SGD","CYBN","IE00B19Z8X17.USD","LU0052756011.USD","IE00BVYPNV92.GBP","US912797GW17.BOND","US5Y.BOND","DKS","US3Y.BOND","IE00B3SWFQ91.USD","IE0002270589.USD","LU0109392836.USD","VTR","US2Y.BOND","US6M.BOND","IEP","SBUX"],"gpt_icon":1},{"id":"2462121085","title":"Cybin Inc. Shareholders Approve Key Decisions","url":"https://stock-news.laohu8.com/highlight/detail?id=2462121085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462121085?lang=en_us&edition=fundamental","pubTime":"2024-08-28 07:37","pubTimestamp":1724801858,"startTime":"0","endTime":"0","summary":"Cybin (TSE:CYBN) has released an update. Cybin Inc., a neuropsychiatry company, recently held its annual and special meeting where shareholders vot...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cybin-inc-shareholders-approve-key-decisions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cybin-inc-shareholders-approve-key-decisions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CYBN","BK4168"],"gpt_icon":0},{"id":"2462267121","title":"Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2462267121","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462267121?lang=en_us&edition=fundamental","pubTime":"2024-08-28 07:01","pubTimestamp":1724799660,"startTime":"0","endTime":"0","summary":"Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:. Each of the nominees for election as director listed in Cybin’s management information circular dated July 24, 2024 were elected as directors of Cybin for the ensuing year or until their successors are elected or appointed. Voting results are set out below:. The resolution to approve the consolidation of the issued and outstanding common shares of the Company by a ratio of up to 50:1 was approved by at least two-thirds of votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:. The resolution to approve certain amendments to Cybin’s equity incentive plan was approved by a majority of votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_W0zNPWFSk7LYBZMyg9wpg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/88045786c9587f1053e0d0835c783b3a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_W0zNPWFSk7LYBZMyg9wpg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/88045786c9587f1053e0d0835c783b3a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-announces-results-annual-special-230100698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CYBN","BK4168"],"gpt_icon":0},{"id":"2461452753","title":"Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report","url":"https://stock-news.laohu8.com/highlight/detail?id=2461452753","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461452753?lang=en_us&edition=fundamental","pubTime":"2024-08-24 06:34","pubTimestamp":1724452452,"startTime":"0","endTime":"0","summary":"The U.S. FDA has been conducting interviews with several individuals familiar with clinical trials conducted by Lykos Therapeutics for its rejected MDMA-based PTSD therapy as it investigates potential improprieties.  The Wall Street Journal reported that at four individuals have been interviewed about the possibility some side effects -- including suicidal thoughts -- were not reported.  The newspaper noted that one person interviewed was asked about the techniques used in giving the therapy, called midomafetamine. Earlier in August, the FDA issued a Complete Response Letter to Lykos on the drug and asked the company to conduct an additional trial. Less than a week later, Lykos said it would lay off 75% of its workforce. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Cle","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971235/image_1286971235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4143520-trials-psychedlic-drug-candidate-ptsd-under-scrutiny-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4547","MNQmain","DRUG","ENVB","QQQ","CMND","BK4007","PSQ",".IXIC","NQmain","QID","SPRC","ATNF","CYBN","BK4539","SQQQ","SEEL","BK4168","ATAI","GHRS","QLD","MNMD","CMPS","BK4139","TQQQ"],"gpt_icon":1},{"id":"2459401548","title":"Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2459401548","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459401548?lang=en_us&edition=fundamental","pubTime":"2024-08-16 03:02","pubTimestamp":1723748562,"startTime":"0","endTime":"0","summary":"Lykos Therapeutics, the privately held psychedelic drug developer, is letting go of 75% of its employees following the U.S. FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board.  David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine , Atai Life Sciences , COMPASS Pathways , Cybin , and GH Research . Nano-caps include 180 Life Sciences , Enveric Biosciences , Seelos Therapeutics , SciSparc , Bright Minds Biosciences , and Clearmind Medicine .","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/882024294/image_882024294.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4140729-lykos-laying-off-75-workforce-following-fda-rejection-psychedelic-drug-ptsd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SPRC","BK4007","ATNF","MNQmain","ATAI","MNMD","PSQ","CMND","BK4547","BK4168","BK4539","NQmain","GHRS",".IXIC","QID","ENVB","CMPS","BK4139","SQQQ","DRUG","CYBN","SEEL","TQQQ","QLD"],"gpt_icon":1},{"id":"2459477032","title":"Psychedelic Stocks: Focus On Their Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2459477032","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459477032?lang=en_us&edition=fundamental","pubTime":"2024-08-16 00:30","pubTimestamp":1723739400,"startTime":"0","endTime":"0","summary":"Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD and Lykos Therapeutics . Recent news a blessing in disguise for Cybin, COMPASS Pathways and MindMed ?Trial data and cash in the bank are top signifiers of success . How Atai fell behind and dropped out of the conversation . Upcoming catalysts - patience required . For psychedelic medicine, does it matter who's in the White House ?JN: Yeah, yeah. So this past week was a big moment in the psychedelic medicine space. This - Lykos and its former incarnation, MAPS, which is a nonprofit, have been working to bring MDMA, worked with the FDA since the 80s and their clinical trials for over a decade. So this was to be a culmination of decades of work for like a really dedicated group of psychedeli","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1415526050/image_1415526050.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1415526050/image_1415526050.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4714883-psychedelic-stocks-focus-on-their-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CYBN","MNMD","BK4007","ATAI","PSIL","CMPS","BK4139","BK4547","BK4539","BK4168"],"gpt_icon":0},{"id":"2459902756","title":"Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer","url":"https://stock-news.laohu8.com/highlight/detail?id=2459902756","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459902756?lang=en_us&edition=fundamental","pubTime":"2024-08-13 22:17","pubTimestamp":1723558628,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4168","CYBN","BK4007"],"gpt_icon":0},{"id":"2459902273","title":"Cybin to Begin Phase 3 Trial of Treatment for Major Depressive Disorder This Summer","url":"https://stock-news.laohu8.com/highlight/detail?id=2459902273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459902273?lang=en_us&edition=fundamental","pubTime":"2024-08-13 22:17","pubTimestamp":1723558628,"startTime":"0","endTime":"0","summary":"Cybin  Tuesday said it expects to begin phase 3 testing of its CYB003 drug candidate to treat major depressive disorder later this summer following a recent Type B initial breakthrough therapy meeting with the US Food and Drug Administration.The Canadian drug maker plans to implement several measures to reduce the risk of functional unblinding during the upcoming trial, including using a three-arm design with a high dose, mid-dose and placebo arm and relying on independent, blinded raters who will not have any information on the trial subject's dosing, it said.During phase 2 testing, the company said CYB003 showed a robust and sustained effect, with 75% of the patients with depression still in remission four months after receiving two 16-milligram doses. Cybin said it anticipates reporting 12-month efficacy data from the mid-stage study in Q4.Cybin shares were about 3% lower in recent trading.Price: 0.26, Change: -0.01, Percent Change: -3.02","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CYBN","BK4007","BK4168"],"gpt_icon":0},{"id":"2459971927","title":"Cybin Inc: Expects to Initiate Phase 3 Pivotal Trial in Late Summer 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2459971927","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459971927?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:30","pubTimestamp":1723548600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUAHCWRF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4168","CYBN"],"gpt_icon":0},{"id":"2459971909","title":"Cybin Inc: Company to Report 12-Month Phase 2 Efficacy Data for Cyb003 in Major Depressive Disorder (\"Mdd\") in Q4 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2459971909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459971909?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:30","pubTimestamp":1723548600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUAHCWRF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYBN","BK4139","BK4168","ABVC","BK4007"],"gpt_icon":0},{"id":"2459719789","title":"Cybin Inc: Pivotal Trial Designs Incorporate Elements to Address Functional Unblinding","url":"https://stock-news.laohu8.com/highlight/detail?id=2459719789","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459719789?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:30","pubTimestamp":1723548600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240813:nTUAHCWRF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYBN","BK4168","BK4007"],"gpt_icon":0},{"id":"2459971710","title":"Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2459971710","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459971710?lang=en_us&edition=fundamental","pubTime":"2024-08-13 19:30","pubTimestamp":1723548600,"startTime":"0","endTime":"0","summary":"- Company expects to initiate Phase 3 pivotal trial in late summer 2024 -. - Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies -. - Pivotal trial designs incorporate elements to address functional unblinding -. - Company to report 12-month Phase 2 efficacy data for CYB003 in Major Depressive Disorder  in Q4 2024 -. TORONTO, August 13, 2024----Cybin Inc.   , a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it held a Type B Initial Breakthrough Therapy Meeting with the U.S. Food and Drug Administration  late last week in Washington, D.C. The Company plans to initiate its Phase 3 pivotal trial of CYB003 for the adjunctive treatment of MDD in late summer of 2024.The pivotal study program will include one study with a three-arm design with a high dose, mid-dose, and placebo ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GAQl8pM.4gnk4EcZ8NyNVg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c732cf80c6347e09572f5c98ea8760b6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GAQl8pM.4gnk4EcZ8NyNVg--~B/aD0yNjg7dz00NjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c732cf80c6347e09572f5c98ea8760b6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-announces-completion-fda-type-113000811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CYBN","BK4168","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cybin.com","stockEarnings":[{"period":"1week","weight":-0.0365},{"period":"1month","weight":0.0412},{"period":"3month","weight":-0.0797},{"period":"6month","weight":-0.4136},{"period":"1year","weight":-0.545},{"period":"ytd","weight":-0.4063}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":0.04},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.1052},{"period":"1year","weight":0.3498},{"period":"ytd","weight":0.2055}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.035929},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037459},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.054271},{"month":4,"riseRate":0,"avgChangeRate":-0.183109},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.013183},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.000728},{"month":7,"riseRate":1,"avgChangeRate":0.050192},{"month":8,"riseRate":0.333333,"avgChangeRate":0.185712},{"month":9,"riseRate":0.25,"avgChangeRate":-0.038237},{"month":10,"riseRate":0.5,"avgChangeRate":0.011398},{"month":11,"riseRate":0,"avgChangeRate":-0.231533},{"month":12,"riseRate":0,"avgChangeRate":-0.158179}],"exchange":"AMEX","name":"Cybin Inc","nameEN":"Cybin Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cybin Inc(CYBN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cybin Inc(CYBN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cybin Inc,CYBN,Cybin Inc股票,Cybin Inc股票老虎,Cybin Inc股票老虎国际,Cybin Inc行情,Cybin Inc股票行情,Cybin Inc股价,Cybin Inc股市,Cybin Inc股票价格,Cybin Inc股票交易,Cybin Inc股票购买,Cybin Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cybin Inc(CYBN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cybin Inc(CYBN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction